Monitoring Adverse Reactions to Steroid Therapy in Children

Indian Pediatrics

Volumn 41, Issue 4, 2004, Pages 349-357

  Seth, Anju ^a,b   Aggarwal, Anu ^a  

^a KALAWATI SARAN CHILDREN'S HOSPITAL   (India)

^b 601 Parivar Apartment ^*  (India)

Author keywords

Adverse effects; Cortico steroids

Indexed keywords

CORTICOSTEROID; GLUCOCORTICOID;

ASTHMA; AVASCULAR NECROSIS; BLOOD PRESSURE; BODY HEIGHT; BODY WEIGHT; CATARACT; CUSHING DISEASE; DENSITOMETRY; DISEASE PREDISPOSITION; ELECTROLYTE BLOOD LEVEL; GLAUCOMA; GLUCOSE BLOOD LEVEL; GROWTH RETARDATION; HUMAN; HYPERGLYCEMIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LOW DRUG DOSE; MOOD DISORDER; MYOPATHY; OSTEOPENIA; OSTEOPOROSIS; PANCREATITIS; PSEUDOTUMOR; PSYCHOSIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; STOMACH HEMORRHAGE; STOMACH ULCER; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; CHILD; CUSHING SYNDROME; DRUG EFFECT; GASTROINTESTINAL TRACT;

CHILD; CUSHING SYNDROME; GASTROINTESTINAL TRACT; GLAUCOMA; GLUCOCORTICOIDS; HUMANS; HYPERGLYCEMIA; OSTEONECROSIS;

EID: 1942533690     PISSN: 00196061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Axelrod L. Glucocorticoid therapy. In: Degroot LJ and Jameson JL, editors. Endocrinology, 4th ed. Philadelphia: WB Saunders Co; 2001. p 1671-1682.
2. Cassidy JT, Pelty RE. Basic concepts of drug therapy. In: Cassidy JT; and Pelty RE, editors. Textbook of Pediatric Rheumatology. 3rd ed. Philadelphia: W.B. Saunders Co: 1995; p 67-107.
3. Tiapi C, Chrouson GP. Glucocorticoids. In: Yaffe SJ, Aranda JV, editors. Pediatric Pharmacology. Therapeutic Principles in Practice. 2nd ed. Philadelphia: W.B. Saunders Co 1992; p 466-475.
4. Hoogweif B, Danesc RD. Drug selection and management of corticosteroid related diabetes mellitus. Rheum Dis Clin North Am 1999; 25: 489-505.
5. Ton Shoff B, Haffner D, Mehli O, Dietz. M, Ruder H, Blum W et al. Efficacy and safety of GH treatment in short children with renal allograft: Three years experience. Kidney Int 1993; 44: 199-207.
6. Cave A, Arlett P, Lee E. Inhaled and nasal corticosteroids: Factors affecting the risk of systemic adverse effects. Pharmacol Therapy 1999; 83: 153-179.
7. Byyney RL. Withdrawal from glucocorticoid therapy. N Engl J Med 1976; 295: 30-32.
8. Jacobs TP, Whitlock RT, Edsall J, Holub DA. Addisonian crisis while taking high dose glucocorticoids. J Am Med Assoc 1988; 260: 2082-2084.
9. Tivanou T, Ferriman D, James VHT. Recovery of HPA function after corticosteroid therapy. Lancet 1979; I: 630-633.
10. Cowell CT. Short stature. In: Brook CGD, editor. Clinical Pediatric Endocrinology. 3rd ed. Oxford: Blackwell Science Ltd 1995; 136-172.
11. Sadeghi NA, Senior B. Adrenal function, growth and insulin in patients treated with corticoids on alternate days. Pediatrics 1969; 443: 277-283.
12. Kristmundsdottir F, David TS. Growth impairment in children with atopic eczema. J R Soc Med 1987; 80: 9-12.
13. Heuck C, Wolters OD, Hansen M, Kollerup G. Correlation between short term lower leg growth and markers of collagen turnover in asthmatic adolescents treated with inhaled budesonide 800 μg daily. Steroids 1997; 62: 659-664.
14. Skoner DP. Balancing safety and efficacy in pediatric asthma management. Pediatrics 2002; 109: 381-392.
15. Bessler W. Vertebral growth arrest lines after Cushings syndrome. Diag Imaging 1982; 51: 311.
16. Whitworth JA, Mangos GJ, Kelly D. Cushing, cortisol and cardiovascular disease. Hypertension 2000; 36: 912-916.
17. Conn HO, Poynard T. Corticosteroids and peptic ulcer: Meta-analysis of adverse events during steroid therapy. J Int Med 1994; 236: 619-632.
18. Oppenheimer EH, Boitnolt JK. Pancreatitis in children following adrenal corticosteroid therapy. Bull John Hopkin Hosp 1960; 107: 297-299.
19. Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin 1992; 3: 505-512.
20. Giles CL, Mason GL, Duff IF, Mclean JA, Mich AA. The association of cataract formation and systemic corticosteroid therapy. J Am Med Assoc 1962; 182: 719-723.
21. Brocklebank JT, Harcourt RB, Meadow SR. Corticosteroid induced cataracts in idiopathic nephrotic syndrome. Arch Dis Child 1982; 53: 30-34.
22. Lukert BP, Raisz LG. Glucocorticoid induced osteoporosis: Pathogenesis and management. Ann Intern Med 1990; 112: 352-364.
23. Libanati CR, Baylink DJ. Prevention and treatment of glucocorticoid induced osteoporosis. A pathogenic perspective. Chest 1992; 102: 1426-1435.
24. American College of Rheumatology Task Force on Osteoporosis Guidelines: Recommendations for prevention and treatment of glucocorticoid induced osteoporosis. Arthritis Rheum 1996; 39: 1791-1801.
25. Virik K, Karapetis C, Droufakou S, Harper P. Avascular necrosis of bone: Hidden risk of glucocorticoids used as antiemetics in cancer chemotherapy. Int J Clin Pract 2001; 55: 344-345.
26. Askari A, Vignos PJ Jr, Moskowitch RW. Steroid myopathy in connective tissue disease. Am J Med 1976; 61: 485-492.
27. Dale DC, Fauci AS, Wolff SM. Alternate day prednisone: Leucocyte kinetics and susceptibility to infections. N Engl J Med 1974; 291: 1154-1160.
28. Torack RM. Fungus infections associated with antibiotic and steroid therapy. Am J Med 1957; 22: 872-878.
29. Forest MG. Adrenal steroid excess. In: Brook CGD editor. Clinical Pediatric Endocrinology 3rd edn. Oxford: Blackwell Science Ltd. 1995. p 499-535.